TCR deal spree in­ten­si­fies as Roche com­mits up to $2B in Adap­tive Biotech to de­vel­op per­son­al­ized can­cer drugs

The ap­petite for TCR ther­a­pies and their po­ten­tial to tar­get sol­id tu­mors — a lim­i­ta­tion of ex­ist­ing cel­lu­lar ther­a­pies — has bur­geoned, fu­el­ing a string of deals.  On Fri­day, Roche’s Genen­tech agreed to fork out a meaty $300 mil­lion up­front for ac­cess to Adap­tive Biotech­nolo­gies’ tech plat­form, which is de­signed to iden­ti­fy T-cell re­cep­tors (TCRs) for ther­a­peu­tic use. The deal, which of­fers Adap­tive up to $2 bil­lion over time in mile­stone pay­ments, will be used to de­vel­op per­son­al­ized can­cer ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA